-

12:53:25 AM

IPHA Stock News

IPHA - Innate Pharma

09/23/22 1:00 AM

Nasdaq : IPHA

clinical trial

Innate Pharma Presents Data From Ongoing Phase 2 TELLOMAK Trial Demonstrating Clinical Activity of Lacutamab in Advanced Mycosis Fungoides

Martine Bagot, Head of the Dermatology Department, Saint Louis Hospital, Paris. "We are pleased to see that lacutamab continues to show clinical activity in these heavily-pretreated patients with mycosis fungoides, confirming our hypothesis that lacutamab, a KIR3DL2 targeted agent, could provide benefit to patients with tumors expressing the target," said...

RHEA-AI

neutral

09/15/22 1:00 AM

Nasdaq : IPHA

earnings

Innate Pharma Reports First Half 2022 Financial Results and Business Update

Innate Pharma SA today reported its consolidated financial results for the six months ended June 30, 2022. The ANKET TM technology is the engine for development of our robust pipeline of much needed novel solutions to treat cancer." said Mondher Mahjoubi, Chief Executive Officer of Innate Pharma." We continue to see progress for monalizumab in the early...

RHEA-AI

neutral

09/08/22 1:00 AM

Nasdaq : IPHA

Innate Pharma Announces Conference Call and Webcast for First Half 2022 Business Update

Innate Pharma SA, today announced that the Company will hold a conference call on Thursday, September 15, 2022, at 2 p.m. CEST/ 8 a.m. EDT, to give an update on business progress during the first half of 2022.. Mondher Mahjoubi, Chief Executive Officer Joyson Karakunnel, Executive Vice President, Chief Medical Officer Fr?d?ric Lombard, Senior Vice President, Chief...

RHEA-AI

neutral

09/05/22 1:00 AM

Nasdaq : IPHA

conferencesclinical trial

Innate Pharma to Present Lacutamab PTCL Phase 1b Design and ANKET(TM) Platform at ESMO 2022

Innate Pharma SA today announced that the following presentations will be presented at the ESMO Annual Meeting 2022 taking place from 9 to 13 September 2022, in Paris, France. A multi-center Phase Ib trial evaluating the safety and efficacy of lacutamab in patients with relapsed/refractory peripheral T-cell lymphoma that express KIR3DL2- Abstract Number:...

RHEA-AI

neutral

08/23/22 1:00 AM

Nasdaq : IPHA

conferences

Innate Pharma to Participate in Upcoming Investor Conferences

Headquartered in Marseille, France with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US. Learn more about Innate Pharma at www.innate-pharma.com. Information about Innate Pharma shares:.

RHEA-AI

neutral

08/08/22 1:00 AM

Nasdaq : IPHA

Number of Shares and Voting Rights of Innate Pharma as of August 1, 2022

Pursuant to the article L. 233-8 II of the French" Code de Commerce" and the article 223-16 of the French stock-market authorities General Regulation, Innate Pharma SA releases its total number of shares outstanding as well as its voting rights as at August 1, 2022:. It is released so as to ensure that the market is adequately informed, in accordance with the...

RHEA-AI

neutral

08/01/22 1:00 AM

Nasdaq : IPHA, AZN

clinical trial

Innate Pharma Provides Update on AstraZeneca-Sponsored INTERLINK-1 Phase 3 Study

Innate Pharma SA, today announced that a planned futility interim analysis of the INTERLINK-1 Phase 3 study sponsored by AstraZeneca did not meet a pre-defined threshold for efficacy. Based on this result and the recommendation of an Independent Data Monitoring Committee, AstraZeneca has informed Innate that the study will be discontinued.

RHEA-AI

neutral

07/28/22 1:00 AM

Nasdaq : IPHA

conferences

Innate Pharma to Participate in Upcoming Investor Conference

Headquartered in Marseille, France with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US. Learn more about Innate Pharma at www.innate-pharma.com. Information about Innate Pharma shares:.

RHEA-AI

neutral

07/21/22 1:00 AM

Nasdaq : IPHA

Second Innate Pharma NK Cell Engager Selected by Sanofi as Drug Candidate for Development

Innate Pharma SA today announced that Sanofi has made the decision to progress IPH6401/SAR' 514 into investigational new drug- enabling studies, triggering a EUR3 million milestone payment. IPH6401/SAR' 514 is a BCMA-targeting NK cell engager using Sanofi' s proprietary CROSSODILE (R) multi-functional platform, which comprises the...

RHEA-AI

very positive

06/23/22 1:00 AM

Nasdaq : IPHA

conferences

Innate Pharma to Participate in Upcoming Investor Conference

Headquartered in Marseille, France with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US. Learn more about Innate Pharma at www.innate-pharma.com. Information about Innate Pharma shares:.

RHEA-AI

neutral

1 2 3 4 5 6 7 8 9 Next